



Wednesday, September 24, 2008

Opening and Keynote Addresses

8:00 – 9:30 am
Salons III and IV

Robin A. Robinson, PhD

Deputy Assistant Secretary for Preparedness and Response
Director, Office of Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services

Introduction of Secretary Michael O. Leavitt by

RADM W. Craig Vanderwagen, MD

Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

Secretary Michael O. Leavitt

U.S. Department of Health and Human Services

Robert P. Kadlec, MD

Special Assistant to the President for Homeland Security
Senior Director, Biodefense Policy
Homeland Security Council, The Executive Office of the President

RADM W. Craig Vanderwagen, MD

Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services



B R E A K

Salons I and II

9:30 – 9:50 am

E X H I B I T S

8:00 am – 7:00 pm
Salons I and II

PHEMCE PARTNER EXHIBITS

U.S. DEPARTMENT OF DEFENSE

- Armed Forces Radiobiology Research Institute (AFRRI) ▪

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

- Centers for Disease Control and Prevention (CDC) Radiation Studies Branch ▪

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES; NATIONAL INSTITUTES OF HEALTH

- Biodefense and Emerging Infections Resource Program, NIAID ▪
▪ National Library of Medicine ▪

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

OFFICE OF THE ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE

- Biomedical Advanced Research and Development Authority (BARDA) ▪
▪ MedicalCountermeasures.gov ▪

- U.S. DEPARTMENT OF HOMELAND SECURITY ▪

BARDA INDUSTRY DAY EXHIBITS

CLEVELAND BIOLABS, INC.

- Single Injection of Novel Radioprotector CBLB502 Rescues Lethally Irradiated Non-Human Primates ▪

NATIONAL WEATHER SERVICE, NATIONAL OCEANIC AND ATMOSPHERIC ADMINISTRATION

- But I'm Not a Meteorologist: U.S. Public and Private Weather Enterprise Support to the Medical Community ▪

STATE UNIVERSITY OF NEW YORK AT BUFFALO AND MEDICAL CONSERVATION DEVICES, LLC

- Aseptic Shared Ventilation: An Alternative to Pandemic Ventilator Rationing ▪



Wednesday, September 24, 2008

**Federal Progress in
Medical Countermeasure Preparedness**

**9:50 am – 12:30 pm
Salons III and IV**

Moderator: Carol D. Linden, PhD

Principal Deputy Director, Office of Biomedical Advanced Research and Development Authority
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

Jon R. Krohmer, MD, FACEP

Acting Assistant Secretary and Chief Medical Officer
Office of Health Affairs
U.S. Department of Homeland Security

Michael Kurilla, MD, PhD

Director, Office of Biodefense Research Affairs, Division of Microbiology and Infectious Diseases
Associate Director for Biodefense Product Development, National Institute of Allergy and Infectious Diseases
National Institutes of Health
U.S. Department of Health and Human Services

Robin A. Robinson, PhD

Deputy Assistant Secretary for Preparedness and Response
Director, Office of Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services

Jean D. Reed, SES

Special Assistant to the Secretary of Defense for Chemical and Biological Defense and Chemical Demilitarization Programs
Office of the Assistant to the Secretary of Defense (Nuclear, Chemical, and Biological Programs)
U.S. Department of Defense

Greg Burel

Director, Division of Strategic National Stockpile
Coordinating Office for Terrorism Preparedness and Emergency Response
Centers for Disease Control and Prevention
U.S. Department of Health and Human Services

Kevin Yeskey, MD

Deputy Assistant Secretary for Preparedness and Response
Director, Office of Preparedness and Emergency Operations
U.S. Department of Health and Human Services



LUNCH ON YOUR OWN

12:30 – 2:00 pm



This icon indicates sessions that will be webcast live
and that will be available for viewing
on the BARDA website beginning October 2008.

WWW.HHS.GOV/ASPR/BARDA



Wednesday, September 24, 2008

BARDA INDUSTRY DAY: Session I

2:00 – 4:00 pm

Salon V

**ANTHRAX
THERAPEUTICS**

*Moderator: Michael A. Balady, PhD, MPH
Director for Acquisition Management Systems;
Office of Biomedical Advanced Research and
Development Authority;
U.S. Department of Health and Human Services*

2:00 - 2:30 pm

**Valortim™, an Anti-toxin
Monoclonal Antibody,
for the Treatment and
Post-exposure Prophylaxis
of Inhalational Anthrax**

*Matthew Meldorf
PharmAthene, Inc.*

2:30 - 3:00 pm

**Development of a Human
Anthrax Immune Globulin
Intravenous (AIGIV)
Therapeutic Agent for
Treatment of Anthrax Disease**

*Ajoy Chakrabarti
Emergent Biosolutions*

3:00 - 3:30 pm

**An Immunoadhesin
Therapy for
Inhalation Anthrax**

*Archana Belle
Planet Biotechnology, Inc.*

3:30 - 4:00 pm

**Characterization of *B. anthracis*
Inhalation Model in Cynomolgus
Monkeys and Rabbits for
Evaluation of Therapeutic
Treatment**

*Thi-Sau Migone
Human Genome Sciences, Inc.*

Salon VI

**VACCINE
INNOVATIONS**

*Moderator: Gerald R. Kovacs, PhD
Acting Associate Director for CBRN Programs;
Office of Biomedical Advanced Research and
Development Authority;
U.S. Department of Health and Human Services*

2:00 - 2:30 pm

**Alternative Vaccine Delivery:
Advanced Intranasal Delivery
Platform for Packaging,
Stockpiling and Dispensing
Liquid and Reconstituted
Emergency Vaccines and
Bioterror Countermeasures in
Chaotic and Austere Conditions**

*Timothy Sullivan
Mystic Pharmaceuticals*

2:30 - 3:00 pm

**The LT Adjuvant Patch
as a Platform Technology to
Enhance Biodefense Vaccines**

*Nigel Thomas
Intercell USA, Inc.*

3:00 - 3:30 pm

**The Broadly Applicable
alphaGal Technology
for Antiviral Vaccines**

*Ramon Flick
BioProtection Systems Corporation*

3:30 - 4:00 pm

**Thermo-stabilization to Enable
Extended Ambient Storage
of Viral Vaccines**

*Andre Habel
Stabilitech Ltd*

Jefferson Room

**CHEMICAL, RADIOLOGICAL,
AND NUCLEAR
THERAPEUTICS**

*Moderator: Ronald Manning, PhD
Branch Chief, Chemical, Radiological, and Nuclear
Medical Countermeasures; Office of Biomedical
Advanced Research and Development Authority;
U.S. Department of Health and Human Services*

2:00 - 2:30 pm

**Rectal Diazepam in
Nerve Agent Attacks:
Efficacy in Seizure Control
and Cognitive/Behavioral
Recovery**

*Romy Nocera
Valeant Pharmaceuticals*

2:30 - 3:00 pm

**Effectiveness of Donepezil,
Rivastigmine and (±)Huperzine-A
in Preventing Soman Acute
Toxicity and Lethality:
Comparison with Galantamine**

*Edson Albuquerque
University of Maryland School of Medicine*

3:00 - 3:30 pm

**Developing Treatments for
Chemical Weapon Attacks:
The UMDNJ-Rutgers University
CounterACT Research Center
of Excellence**

*Jeffrey Laskin
UMDNJ-Robert Wood Johnson
Medical School*

3:30 - 4:00 pm

**Therapeutic Solution for the
Mitigation of the Hematopoietic
Syndrome Resulting from Acute
Exposure to Ionizing Radiation**

*Lena A. Basile
Neumedicines, Inc.*



Wednesday, September 24, 2008

**Medical Countermeasures at the Point of Care
Session I**

**2:00 – 3:00 pm
Salons III and IV**

Moderator: Matthew Minson, MD
Senior Medical Officer for Strategic Initiatives
Office of Policy, Strategic Planning, and Communications
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

THE PUBLIC READINESS AND EMERGENCY PREPAREDNESS (PREP) ACT

Brian Kamoie, JD, MPH
Deputy Assistant Secretary for Preparedness and Response
Director, Office of Policy, Strategic Planning, and Communications
U.S. Department of Health and Human Services

ADDRESSING END USER QUESTIONS ABOUT THE EMERGENCY USE AUTHORIZATION

CDR Carmen Maher, BSN, MA, RN, RAC
Policy Analyst
Office of Counterterrorism and Emerging Threats
Office of the Commissioner
Food and Drug Administration
U.S. Department of Health and Human Services

Stephen Papagiotas, MPH
Public Health Advisor / Emergency Coordinator
Division of Bioterrorism Preparedness and Response
Centers for Disease Control and Prevention
U.S. Department of Health and Human Services

Susan E. Gorman, PharmD, MS
Associate Director for Science, Division of Strategic National Stockpile
Coordinating Office for Terrorism Preparedness and Emergency Response
Centers for Disease Control and Prevention
U.S. Department of Health and Human Services

REQUESTING FEDERAL MEDICAL COUNTERMEASURE ASSETS

Kevin Yeskey, MD
Deputy Assistant Secretary for Preparedness and Response
Director, Office of Preparedness and Emergency Operations
U.S. Department of Health and Human Services

Greg Burel
Director, Division of Strategic National Stockpile
Coordinating Office for Terrorism Preparedness and Emergency Response
Centers for Disease Control and Prevention
U.S. Department of Health and Human Services





Wednesday, September 24, 2008

Medical Countermeasures at the Point of Care, Session I *continued*

3:00 – 4:00 pm

The Role of Point-of-Care Diagnostics
in Triage and Treatment Decisions

Salons III and IV

Moderator: Jerome A. Donlon, MD, PhD

POINT-OF-CARE DIAGNOSTIC NEEDS
FOR CHEMICAL, BIOLOGICAL, RADIOLOGICAL, AND NUCLEAR THREATS

Jerome A. Donlon, MD, PhD

Chief Science Advisor

Office of Biomedical Advanced Research and Development Authority

Office of the Assistant Secretary for Preparedness and Response

U.S. Department of Health and Human Services

THE INFLUENZA POINT-OF-CARE DIAGNOSTICS EXPERIENCE

Roxanne Shively, MS, MT (SM)

Project Officer

Office of Biomedical Advanced Research and Development Authority

Office of the Assistant Secretary for Preparedness and Response

U.S. Department of Health and Human Services

END USER CONSIDERATIONS

Luciana Borio, MD

Senior Associate

The Center for Biosecurity of the University of Pittsburgh Medical Center

Baltimore, Maryland

REGULATORY PATHS FOR POINT-OF-CARE DIAGNOSTICS

Sally A. Hojvat, PhD

Director, Division of Microbiology Devices

Office of In-vitro Diagnostic Device Evaluation and Safety

Center for Devices and Radiological Health

Food and Drug Administration

U.S. Department of Health and Human Services

QUESTIONS FOR THE PANEL



B R E A K

Salons I and II

4:00 – 4:20 pm



Wednesday, September 24, 2008

BARDA INDUSTRY DAY: Session II

4:20 – 6:00 pm

Salon V

**ANTHRAX
THERAPEUTICS**
continued

Moderator: Matthew Lawlor, PhD
Program Analyst
Office of Biomedical Advanced Research
and Development Authority
U.S. Department of Health and Human Services

4:20 - 4:45 pm

**TR-701: A New
OXAZOLIDINONE Therapeutic
with Activity Against *Bacillus
anthracis* and a Broad Spectrum
of Clinically Relevant Drug-
Resistant Pathogens**

Jeffrey Stein
Trius Therapeutics

4:45 - 5:10 pm

**Antisense Screening in
Bacillus anthracis for
Drug Discovery**

Karen Shaw
Trius Therapeutics

Salon VI

**PLATFORM TECHNOLOGIES
AND
DIAGNOSTICS**

Moderator: Dawn Myscofski, PhD, MBA
Deputy Director, Policy, Planning, and
Requirements Division
Office of Biomedical Advanced Research and
Development Authority
U.S. Department of Health and Human Services

4:20 - 4:45 pm

**Development of a Clinical Stage
Electroporation Delivery Platform
to Enhance DNA Vaccines**

Brian Livingston
Ichor Medical Systems

4:45 - 5:10 pm

**Technology Platform for
Rapid Identification of Highly
Pathogenic Viruses**

Ida-Maria Sintorn
Vironova AB

5:10 - 5:35 pm

**Point-of-Care and Laboratory
Diagnostics for Detection
of Potentially Pandemic
Influenza Strains**

George Sigal
Meso Scale Diagnostics, LLC

5:35 - 6:00 pm

**Rapid Clinical Surge-Testing for
Biodefense and Emerging
Infectious Disease**

Don Straus
First Light Biosciences

Jefferson Room

**RADIOLOGICAL
AND NUCLEAR
THERAPEUTICS**

Moderator: Joanna M. Prasher, PhD
Senior Policy Analyst
Office of Biomedical Advanced Research and
Development Authority
U.S. Department of Health and Human Services

4:20 - 4:45 pm

**Protectan CBLB502 Prevents
and Mitigates Hematopoietic and
Gastrointestinal Acute Radiation
Syndromes by Mobilizing
Multiple Natural Defense
Mechanisms**

Andrei Gudkov
*Cleveland BioLabs, Inc. and
Roswell Park Cancer Institute*

4:45 - 5:10 pm

**SPARED: The Salix Program
of Radioprotector Evaluation
and Development**

Christopher Jahraus
Assurance Oncology Services, LLC

5:10 - 5:35 pm

**Nanotherapeutics Inhaled
Gentamicin and Oral DTPA
Programs**

James Talton
Nanotherapeutics, Inc.



Wednesday, September 24, 2008

Medical Countermeasures at the Point of Care

4:20 – 6:00 pm

Session II: Rapid Medical Countermeasure Dispensing

Salons III and IV

Moderator: Greg Burel

Director, Division of Strategic National Stockpile
Coordinating Office for Terrorism Preparedness and Emergency Response
Centers for Disease Control and Prevention
U.S. Department of Health and Human Services

FEDERAL PREPARATION AND SUPPORT FOR EMERGENCY COMMUNICATIONS

Gretchen Michael

Communications Director
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

STRATEGIES AND SUGGESTIONS

Matthew Minson, MD

Senior Medical Officer for Strategic Initiatives
Office of Policy, Strategic Planning, and Communications
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

DISPENSING AT THE STATE LEVEL: COMMONWEALTH OF VIRGINIA

Robert Mauskopf

State Strategic National Stockpile Planner
Virginia State Department of Health
Richmond, Virginia

THE DEPARTMENT OF HEALTH AND HUMAN SERVICES

CHEMPACK PROGRAM

Steven Adams, MPH

Deputy Director, Division of Strategic National Stockpile
Coordinating Office for Terrorism Preparedness and Emergency Response
Centers for Disease Control and Prevention
U.S. Department of Health and Human Services

THE MEDKITS MODEL

Linda Neff, PhD

Senior Science Officer, Division of Strategic National Stockpile
Coordinating Office for Terrorism Preparedness and Emergency Response
Centers for Disease Control and Prevention
U.S. Department of Health and Human Services

PERSONAL PREPAREDNESS AND ANTHRAX ANTIMICROBIAL MEDKITS

Alan Liss, PhD

Deputy Director, Regulatory and Quality Affairs
Office of the Biomedical Advanced Research and Development Authority
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services





Wednesday, September 24, 2008

BARDA Industry Day Poster Session
and Networking Reception

6:00 – 7:00 pm
Salons I and II

VACCINES

Agostini H EMERGENT BIOSOLUTIONS

Development of a Trivalent LHN ABE Recombinant Botulinum Vaccine

Aman MJ INTEGRATED BIOTHERAPEUTICS INC.

Advanced Development of a Recombinant Staphylococcal Enterotoxin B (SEB) Vaccine (STEBVax)

Catron D SYNTIRON LLC

Iron-regulated Bacterial Surface Proteins as Broadly Protective Vaccines

Gaal M SAFIC PHARMA

Challenges and Strategies for Rapid Construction and Manufacture of Viral Vaccines and Therapeutics

Yokote H THE CHEMO-CERO-THERAPEUTIC RESEARCH INSTITUTE (KAKETSUKEN)

Update of an Attenuated Smallpox Vaccine LC16m8 Research

PLATFORM TECHNOLOGIES

Kincaid R VERITAS, INC.

A Novel, Rapidly Deployable Bacteriophage Vector System for Emergency Preparedness Vaccination

Mann D VASCULAR BIOSCIENCES, INC.

Vascular Pharmacogenomics via Endoarterial Biopsy: A Model for Medical Countermeasures against CBRN Pulmonary Vascular Injuries

Stephen E DEFENCE R&D CANADA

Defence R&D Canada's Nucleic Acid-Based Anti-Viral Program

Wajid A XOMA (US) LLC

Use of Platform Technologies to Accelerate Development and Production of Antibodies against Botulinum Toxin Type A

DIAGNOSTICS / BIODOSIMETRY / BIOASSAY

Aristarkhov A EXIQON *INVITED*

Systematic Approach for Detection of Radiation Exposure

Colston B QUANTALIFE INC.

Quantitative PCR using Picoliter Droplets

D'Costa S BECKMAN COULTER, INC.

The CD4 Initiative: Enabling the Development of a Simple Point of Care Assay for CD4 Testing in HIV Infected Individuals in Resource Limited Settings

Gillet D CEA

Application of Different PCR-Based Technologies for Rapid Screening of Botulinum Neurotoxins A, B, E, F Producing *Clostridium Botulinum*, *Clostridium Baratii*, and *Clostridium Butyricum*



Wednesday, September 24, 2008

BARDA Industry Day Poster Session, *continued*

THERAPEUTICS

Armstrong S DSTL

Recombinant Butyrylcholinesterase (rBuChE) Therapy Following VX Poisoning by the Percutaneous Route: Preliminary Results from Guinea Pig Studies

Benson C ORTHO-MCNEIL-JANSSEN SCIENTIFIC AFFAIRS, LLC

Length of Stay in Hospitalized Community-Acquired Pneumonia (CAP) Patients Treated with Levofloxacin 750 mg IV or Moxifloxacin 400 mg IV

Kirman I ELUSYS THERAPEUTICS

Pharmacokinetic and Safety Parameters of ETI-204, a Therapeutic Monoclonal Antibody Targeting Anthrax Protective Antigen (PA)

McCool WS RXBIO, INC.

Rx100 – A Novel Radioprotectant & Radiomitigator

Meldorf M PHARMATHENE, INC.

Efficacy of Intravenous Valortim™, an Anti-toxin Monoclonal Antibody, in the Treatment of Inhalational Anthrax in the African Green Monkey Model

Mody S ORTHO-MCNEIL-JANSSEN SCIENTIFIC AFFAIRS

Reduced Length of Mechanical Ventilation in Patients with Ventilator Associated Pneumonia Treated with Doripenem versus Imipenem

Orschell C INDIANA UNIVERSITY SCHOOL OF MEDICINE

Effect of a Long-lasting G-CSF in Mitigating Lethality in Mice after Exposure of LD20/30 or LD45/30 Dose of Radiation

Pinyerd H IMMUNEREGEN BIOSCIENCES INC.

Viprovox® Enhances Tamiflu® Safety/Efficacy in Influenza A/H3N2 Exposed Cotton Rat

Ramstedt U UNITHER VIROLOGY

Broad Spectrum Antiviral Therapeutic Based on Iminosugar Derivatives

Repine J UNIVERSITY OF COLORADO DENVER HEALTH SCIENCES CENTER

Ergothioneine Treatment for the Acute Respiratory Distress Syndrome

Ruiz A THE UNIVERSITY OF TEXAS AT AUSTIN

Comparison of Levofloxacin 750mg Daily vs. Ceftriaxone 1g plus Azithromycin 500mg Daily for the Empiric Treatment of Hospitalized Community-Acquired Pneumonia (CAP) Patients

Saward L CANGENE CORPORATION

Correlation of the Immunological Epitopes in the HC50 Region of the Botulinum Toxins with Neutralizing Potency of the Equine Anti-toxin Antibodies

Toth D CANGENE CORPORATION

Characterization of the Immune Response Profile of an Intravenous Immunoglobulin (Cangene AIG-IV) to Anthrax Lethal Toxin with Correlation to In-Vitro Potency

Wilson C ENDACEA, INC.

Efficacy for L-97-1 as a Medical Countermeasure in a Bioterrorism Animal Model of Pneumonic Plague



Thursday, September 25, 2008

Keynote Address

8:00 – 8:15 am
Salons III and IV

Introduction of Deputy Secretary Tevi D. Troy by
Gerald W. Parker, DVM, PhD, MS
Principal Deputy Assistant Secretary
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

PUBLIC HEALTH EMERGENCY MEDICAL COUNTERMEASURE RESPONSE

Tevi D. Troy, PhD
Deputy Secretary
U.S. Department of Health and Human Services



A NATION PREPARED

8:15 – 9:00 am

**Public Health Emergency Medical Countermeasure
Response at the Federal, State, and Local Levels**

Salons III and IV

Moderator: **Gerald W. Parker, DVM, PhD, MS**
Principal Deputy Assistant Secretary
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

HHS SUPPORT FOR STATE MEDICAL COUNTERMEASURE PREPAREDNESS

Stephanie M. Dulin, MBA
Chief, Program Preparedness Branch; Division of Strategic National Stockpile
Coordinating Office for Terrorism Preparedness and Emergency Response
Centers for Disease Control and Prevention
U.S. Department of Health and Human Services

LOCAL PUBLIC HEALTH PREPAREDNESS

Jack Herrmann, MEd, NCC, LMHC
Senior Advisor, Public Health Preparedness
National Association of County and City Health Officials (NACCHO)
Washington, DC

CONCERNS AND INFORMATION NEEDS OF THE GENERAL PUBLIC

Steven M. Becker, PhD
Associate Professor of Public Health
Vice Chair, Department of Environmental Health Sciences
The University of Alabama at Birmingham



EXHIBITS

Salons I and II

8:00 am – 7:00 pm

See page 1 for the List of PHEMCE Partner and BARDA Industry Day Exhibits



Thursday, September 25, 2008

Strategies and Suggestions for
Developing and Sustaining a Biodefense Industry

9:00 – 10:00 am
Salons III and IV

Moderator: Robin A. Robinson, PhD
Deputy Assistant Secretary for Preparedness and Response
Director, Office of Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services

Thomas V. Inglesby, MD
Deputy Director and Chief Operating Officer
The Center for Biosecurity of the University of Pittsburgh Medical Center; Baltimore, Maryland

Patrick J. Scannon, MD, PhD
Executive Vice President, Chief Biotechnology Officer
XOMA (US) LLC; Berkeley, California

Sara Radcliffe, MPH, MP
Vice President, Science and Regulatory Affairs
Biotechnology Industry Organization (BIO); Washington, DC

QUESTIONS FOR THE PANEL



B R E A K

Salons I and II

10:00 – 10:20 am

Progress and Path Forward for BARDA

10:20 am – 12:00 pm
Salons III and IV

Moderator: Monique K. Mansoura, PhD
Director of Policy, Planning, and Requirements Division
Acting Deputy Director, Office of Biomedical Advanced Research and Development Authority
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

WORKING AS AN INDUSTRY PARTNER WITH BARDA

Paul Chaplin, PhD
Executive Vice President, Research and Development and Chief Science Officer
Managing Director, Bavarian Nordic GmbH; Martinsried, Germany

James T. Matthews, PhD
Senior Director, Public Policy, Science and Health Policy; sanofi pasteur; Washington, DC

James H. Davis, PhD, JD
Executive Vice President and General Counsel; Human Genome Sciences; Rockville, Maryland

THE BARDA STRATEGIC PLAN

Robin A. Robinson, PhD
Deputy Assistant Secretary for Preparedness and Response
Director, Office of Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services





Thursday, September 25, 2008

National Biodefense Science Board

12:00 – 12:30pm
Salons III and IV

Moderator: Patricia Quinlisk, MD, MPH
Chairperson, National Biodefense Science Board (NBSB)

MARKETS AND SUSTAINABILITY

MG John S. Parker, MD, FACS, FCCP (U.S. Army, Retired)
Member, National Biodefense Science Board
Chairperson, NBSB Markets and Sustainability Working Group

MEDICAL COUNTERMEASURE RESEARCH AND DEVELOPMENT PROCESSES

Patrick J. Scannon, MD, PhD
Member, National Biodefense Science Board
Chairperson, NBSB Medical Countermeasure Research and Development Processes Working Group

PANDEMIC INFLUENZA

Andrew T. Pavia, MD
Member, National Biodefense Science Board
Chairperson, NBSB Pandemic Influenza Working Group; Co-Chairperson, NBSB Personal Preparedness Working Group

DISASTER MENTAL HEALTH

Patricia Quinlisk, MD, MPH
Chairperson, National Biodefense Science Board
Chairperson, NBSB Disaster Mental Health Subcommittee



Summary Remarks

12:30 – 12:40 pm
Salons III and IV

Carol D. Linden, PhD
Principal Deputy Director
Office of Biomedical Advanced Research and Development Authority
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services



LUNCH ON YOUR OWN

12:40 – 2:00 pm



Thursday, September 25, 2008

BARDA INDUSTRY DAY: Session III

2:00 – 4:00 pm

Salon V

PANDEMIC INFLUENZA
MEDICAL COUNTERMEASURES

Moderator: Michael L. Perdue, PhD
*Acting Director, Division of Influenza and Emerging Diseases
Office of Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services*

2:00 - 2:30 pm

Host-Targeted Protection from Pandemic Influenza, SARS and other Respiratory Threats with Hiltonol® (Poly-ICLC) Nasal Spray: Broad Spectrum Activation of Mucosal Innate and Adaptive Immunity in Mice and Humans

*Andres Salazar
Oncovir, Inc.*

2:30 - 3:00 pm

Update on Development of Fludase® as a Broad-Spectrum Therapeutic and Prophylactic Agent for Pandemic Influenza

*David Wurtman
NexBio, Inc*

3:00 - 3:30 pm

Novel Methods for Mediating Hypercytokinemia in Influenza A (H5N1) Infections

*Jose I. Saldana
National Heart and Lung Institute, Imperial College London*

3:30 - 4:00 pm

A System for Rapid Production of Medical Countermeasures

*Vidadi Yusibov
Fraunhofer USA CMB*

Salon VI

VACCINES

Moderator: Gary L. Disbrow, PhD
*Chief, Smallpox Vaccines and Therapeutics
Office of Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services*

2:00 - 2:30 pm

The Development of a Safer Smallpox Vaccine Suitable for Use in Healthy and Immune Suppressed People

*Paul Chaplin
Bavarian Nordic*

2:30 - 3:00 pm

Current Status of BioThrax® (Anthrax Vaccine Adsorbed) Enhancement Programs

*Gary Nabors
Emergent BioSolutions, Inc.*

3:00 - 3:30 pm

Efficient and Versatile Pan-Filo Vaccine is 100% Effective as a Biodefense Vaccine Against Ebola and Marburg Viruses

*John Y. Dong
GenPhar, Inc.*

3:30 - 4:00 pm

A Pan-Filovirus Vaccine Based on Virus-like Particles (VLPs) against Ebola and Marburg Virus Infection

*Kelly Warfield
Integrated Biotherapeutics, Inc.*



Thursday, September 25, 2008

Medical Countermeasures at the Point of Care
Session III: Responding to a
Radiological or Nuclear Event

2:00 – 4:00 pm
Salons III and IV

Moderator: C. Norman Coleman, MD

Associate Director, Radiation Research Program, National Cancer Institute
Senior Medical Advisor and Chief of the CBRN Team, Office of Preparedness and Emergency Operations
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

NATIONAL RESPONSE PLANNING FOR A RADIOLOGICAL OR NUCLEAR EVENT

B. Tilman Jolly, MD

Associate Chief Medical Officer for Medical Readiness
Office of Health Affairs
U.S. Department of Homeland Security

FEDERAL AND STATE COORDINATION FOLLOWING AN EVENT

Robert C. Whitcomb, Jr., PhD, CHP

Senior Scientific Advisor, Radiation Studies Branch
Centers for Disease Control and Prevention
U.S. Department of Health and Human Services

C. Norman Coleman, MD

Associate Director, Radiation Research Program, National Cancer Institute
Senior Medical Advisor and Chief of the CBRN Team, Office of Preparedness and Emergency Operations
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

CITY PREPAREDNESS EFFORTS

Katherine Uraneck, MD

Senior Medical Coordinator
Healthcare Emergency Preparedness Program
New York City (New York) Department of Health and Mental Hygiene

COUNTY PREPAREDNESS EFFORTS

Glen K. Tao, PharmD

Pharmacy Services Chief, Strategic National Stockpile Coordinator
Emergency Preparedness and Response Program
County of Los Angeles (California) Department of Public Health

HOSPITAL PREPAREDNESS EFFORTS

Mark S. Smith, MD, FACEP

Chairman, Division of Emergency Medicine
Director, ER One
Washington Hospital Center; Washington, DC



B R E A K

Salons I and II

4:00 – 4:20 pm



Thursday, September 25, 2008

BARDA INDUSTRY DAY: Session IV

4:20 – 6:00 pm

Salon V

PANDEMIC INFLUENZA VACCINES

Moderator: Sheng Q. Li, DVM

*Project Officer, Pandemic Influenza Program
Office of Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services*

4:20 - 4:45 pm

**Depot Formulations for a
Single Dose Pandemic Influenza Vaccine**

*Marc Mansour
ImmunoVaccine Technologies, Inc.*

4:45 - 5:10 pm

**Rapid and Efficient Production
of Potent Influenza Vaccines**

*Alan Shaw
VaxInnate Corporation*

5:10 - 5:35 pm

**Live Attenuated Influenza Vaccine –
A Viable Solution to Meet US Pandemic
Preparedness Goals!**

*Alan Taggart
MedImmune*

5:35 - 6:00 pm

**Development of Alphavirus Replicon
Vaccines Against Biological Threat Agents**

*Jonathan Smith
AlphaVax, Inc.*

Salon VI

THERAPEUTICS

Moderator: Kevin Gilligan, PhD

*Branch Chief, Antiviral Drugs Pandemic Influenza
Office of Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services*

4:20 - 4:45 pm

**Discovery and Development of
Antiviral Drugs for Biodefense**

*Dennis Hruby
SIGA Technologies*

4:45 - 5:10 pm

**IC14 is a Potential Countermeasure
for Serious CBRN and Public Health
Threats Including Pandemic Flu,
Blast Injury and Bioterrorism**

*Timothy Axtelle
Implicit Bioscience, Inc.*

5:10 - 5:35 pm

**A Rapidly Responsive Platform
for Antiviral Therapeutics Using
Multi-targeted siRNA Cocktail Against
High-Pathogen Viral Infection**

*Patrick Lu
Sirnaomics, Inc.*



Thursday, September 25, 2008

Medical Countermeasures at the Point of Care

4:20 – 6:00 pm

Session IV: Issues in a Radiological or Nuclear Event

Salons III and IV

Moderator: **Richard J. Hatchett, MD**

Associate Director for Radiation Countermeasures Research and Emergency Preparedness
National Institute of Allergy and Infectious Diseases
National Institutes of Health
U.S. Department of Health and Human Services

STRATEGIC NATIONAL STOCKPILE RESOURCES

Steven Adams, MPH

Deputy Director, Division of Strategic National Stockpile
Coordinating Office for Terrorism Preparedness and Emergency Response
Centers for Disease Control and Prevention
U.S. Department of Health and Human Services

TREATMENT DECISIONS FOLLOWING A RADIATION EVENT

CAPT Judith L. Bader, MD

Senior Medical Advisor
Office of Preparedness and Emergency Operations
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

MEDICAL COMMUNITY PERCEPTIONS, CONCERNS, AND REACTIONS
TO A RADIATION EVENT

Steven M. Becker, PhD

Associate Professor of Public Health
Vice Chair, Department of Environmental Health Sciences
The University of Alabama at Birmingham

BIOASSAYS FOR TREATMENT DECISIONS

Robert L. Jones, PhD

Chief, Inorganic and Radiation Analytical Toxicology Branch
Centers for Disease Control and Prevention
U.S. Department of Health and Human Services

BIODOSIMETRY NEEDS FOR TRIAGE AND POPULATION MONITORING

Ronald Manning, PhD

Project Officer and Branch Chief, Chemical, Radiological, and Nuclear Medical Countermeasures
Office of the Biomedical Advanced Research and Development Authority
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

LONG-TERM HEALTH NEEDS FOLLOWING A RADIATION EVENT

Robert C. Whitcomb, Jr., PhD, CHP

Senior Scientific Advisor, Radiation Studies Branch
Centers for Disease Control and Prevention
U.S. Department of Health and Human Services



BARDA Industry Day Poster Session
and Networking Reception

6:00 – 7:00 pm

Salons I and II

See pages 8 and 9 for the List of Poster Presentations



Friday, September 26, 2008

Medical Countermeasure Preparedness:
An International Perspective

8:00 – 10:00 am
Salons I and II

Moderator: Gerald W. Parker, DVM, PhD, MS
Principal Deputy Assistant Secretary
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

THE FRENCH RNBC PROGRAM

Daniel Gillet, PhD
Coordinator for Biology for the French RNBC Program
Adjoint au Chef du Service d'Ingénierie Moléculaire des Protéines
Institut de Biologie et des Technologies de Saclay, Commissariat à l'Energie Atomique
Gif sur Yvette, France

THE UNITED KINGDOM'S HEALTH PROTECTION AGENCY (HPA)
RESEARCH AND DEVELOPMENT INITIATIVES

Steve Chatfield, PhD
Director
Centre for Emergency Preparedness and Response, Health Protection Agency
United Kingdom

GERMANY'S PRIORITY RESEARCH ISSUES

Gerd Sutter, DVM
Head, Department of Virology
Paul Ehrlich Institute
Langen, Germany

Walter Biederbick, PhD
Head, Federal Information Centre for Biological Safety
Robert Koch Institute
Berlin, Germany

THE CANADIAN CHEMICAL, BIOLOGICAL, RADIOLOGICAL-NUCLEAR, AND
EXPLOSIVES (CBRNE) RESEARCH AND TECHNOLOGY INITIATIVE (CRTI)

Mark A. Williamson, PhD
Deputy Director General, Defense Research and Development Canada (DRDC)
Centre for Security Science
Ottawa, Ontario, Canada

QUESTIONS FOR THE PANEL





Friday, September 26, 2008

At-Risk Populations and Medical Countermeasures: 8:00 – 10:00 am
Current Challenges and Opportunities Salon III

Moderator and Speaker: **Mary Kruger, MPP**
Policy Director, Office of Policy, Strategic Planning and Communications
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

Daniel Dodgen, PhD
Director, Office of At-Risk Individuals, Behavioral Health, and Human Services Coordination
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

CDR Scott Santibañez, MD, MPHTM
Medical Officer and Senior Advisor for Vulnerable Populations, Influenza Coordination Unit
Coordinating Center for Infectious Diseases; Centers for Disease Control and Prevention
U.S. Department of Health and Human Services

Susan R. Cooper, MSN, RN
Commissioner
Tennessee Department of Health
Nashville, Tennessee

Kay Aaby, RN, MPH
Program Coordinator, Public Health Emergency Preparedness and Response
Montgomery County (Maryland) Department of Health and Human Services; Rockville, Maryland



Innovations to Facilitate 8:00 – 10:00 am
Public Health Emergency Response Salons V and VI

Moderator: **Jerome A. Donlon, MD, PhD**
Chief Science Advisor
Office of Biomedical Advanced Research and Development Authority
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

BIOMIMETIC IMMUNE MODELS FOR RAPID VACCINE ASSESSMENT

William Warren, PhD
Chief Executive Officer, VaxDesign Corporation
Orlando, Florida

DISSOLVABLE MICRONEEDLE DELIVERY SYSTEM

Sean Sullivan
Senior Graduate Researcher, School of Chemical and Biomolecular Engineering
Georgia Institute of Technology; Atlanta, Georgia

BREATH ANALYSIS TO DETECT RESPIRATORY DISEASE

Joany Jackman, PhD
Senior Scientist, Johns Hopkins Applied Physics Laboratory
Laurel, Maryland

**TRANSLATION ENHANCING ELEMENTS IN
BIOPHARMACEUTICAL PRODUCTION CELL LINES**

Vincent P. Mauro, PhD
Lead Scientist, Promosome LLC
Associate Professor, Department of Neurobiology, The Scripps Research Institute
La Jolla, California





Friday, September 26, 2008

B R E A K

Salons I and II

10:00 – 10:20 am

Breakout Sessions

10:20 am – 12:00 pm

SESSION A

Performance Measures for Medical Countermeasure
Distribution and Utilization in Public Health Emergency Response

Teal Badge Ribbons in the Jackson Room

Violet Badge Ribbons in the Jefferson Room

Blue Badge Ribbons in the Lee Room

SESSION B

Community Preparedness for All-Hazards Response:
Challenges for Planning

Light Blue Badge Ribbons in Salon I

SESSION C

Building and Sustaining Medical Countermeasure Industries
for CBRN Threats and Pandemic Influenza

Orange Badge Ribbons in Salon IV

Gold Badge Ribbons in Salon V

Green Badge Ribbons in Salon VI

SESSION D

Novel Medical Countermeasure Forward Deployment and Dispensing Models:
Opportunities and Challenges

Brown Badge Ribbons in Salon II

Red Badge Ribbons in Salon III

SEE YOU NEXT YEAR!

HHS PUBLIC HEALTH EMERGENCY MEDICAL COUNTERMEASURES ENTERPRISE
2009 STAKEHOLDERS WORKSHOP & BARDA INDUSTRY DAY

To be held in the Washington, DC area
SEPTEMBER 22 – 24, 2009

Subject to confirmation

Watch the BARDA Website
for Location, Registration, and Abstract Submission Deadlines

WWW.HHS.GOV/ASPR/BARDA